- Home
- TRSG vs CGTX Comparison
TRSG vs CGTX Comparison
Compare TRSG & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRSG
- CGTX
- Stock Information
- Founded
- TRSG 1996
- CGTX 2007
- Country
- TRSG Singapore
- CGTX United States
- Employees
- TRSG N/A
- CGTX N/A
- Industry
- TRSG
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- TRSG
- CGTX Health Care
- Exchange
- TRSG NYSE
- CGTX Nasdaq
- Market Cap
- TRSG 33.4M
- CGTX 30.0M
- IPO Year
- TRSG 2024
- CGTX 2021
- Fundamental
- Price
- TRSG $1.91
- CGTX $0.58
- Analyst Decision
- TRSG
- CGTX Strong Buy
- Analyst Count
- TRSG 0
- CGTX 6
- Target Price
- TRSG N/A
- CGTX $8.30
- AVG Volume (30 Days)
- TRSG 2.9K
- CGTX 809.4K
- Earning Date
- TRSG 12-31-2024
- CGTX 03-25-2025
- Dividend Yield
- TRSG N/A
- CGTX N/A
- EPS Growth
- TRSG N/A
- CGTX N/A
- EPS
- TRSG N/A
- CGTX N/A
- Revenue
- TRSG $14,441,864.00
- CGTX N/A
- Revenue This Year
- TRSG N/A
- CGTX N/A
- Revenue Next Year
- TRSG N/A
- CGTX N/A
- P/E Ratio
- TRSG N/A
- CGTX N/A
- Revenue Growth
- TRSG 9.34
- CGTX N/A
- 52 Week Low
- TRSG $1.91
- CGTX $0.34
- 52 Week High
- TRSG $11.78
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- TRSG N/A
- CGTX 40.43
- Support Level
- TRSG N/A
- CGTX $0.57
- Resistance Level
- TRSG N/A
- CGTX $0.65
- Average True Range (ATR)
- TRSG 0.00
- CGTX 0.05
- MACD
- TRSG 0.00
- CGTX -0.01
- Stochastic Oscillator
- TRSG 0.00
- CGTX 9.46
About TRSG TUNGRAY TECHNOLOGIES INC
Tungray Technologies Inc is an engineer-to-order company that provides custom industrial manufacturing solutions to original equipment manufacturers in the semiconductor, printer, electronics, and home appliance industries. It predominantly generates revenue through the manufacture of custom industrial manufacturing solutions, direct drive and linear DC motors, and induction welding equipment. Geographically, the company generates a majority of its revenue from Singapore and the rest from China.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.